- Career Development
-
Title Announcement and Link Expiration Date Notice of Special Interest: National Cancer Institute Supports Applications for the Mentored Research Scientists Development Awards within the Mission of the Division of Cancer Prevention NOT-CA-24-023 (Use program announcements PA-24-175, PA-24-176, or PA-24-177) 05/08/2029 Mentored Research Scientist Development Award PA-24-175 (Independent Clinical Trial Required)
PA-24-176 (Independent Clinical Trial Not Allowed)
PA-24-177 (Parent K01 Independent Basic Experimental Studies with Humans Required)05/08/2027 The NCI Worta McCaskill-Stevens Career Development Award for Community Oncology and Prevention Research PAR-24-153 (K12 Clinical Trial Optional) 02/19/2027 Notice of Special Interest: NCI Supports Applications for the Mentored Research Scientist Development Awards (K01) within the Mission of the Division of Cancer Prevention NOT-CA-24-023 05/08/2029 NCI Pathway to Independence Award for Early-Stage Postdoctoral Researchers PAR-23-286 (K99/R00 - Independent Clinical Trial Not Allowed)
PAR-23-287 (K99/R00 - Independent Clinical Trial Required)
PAR-23-288 (K99/R00 - Independent Basic Experimental Studies with Humans Required)10/15/2026 NCI Research Specialist (Laboratory-based Scientist) Award PAR-23-242 (R50 Clinical Trial Not Allowed) 11/04/2025 - Clinical Trials
-
Title Announcement and Link Expiration Date Cancer Prevention and Control Clinical Trials Planning Grant Program PAR-22-173 (R34 Clinical Trials Optional)
PAR-22-174 (U34 Clinical Trials Optional)05/08/2025 Cancer Prevention and Control Clinical Trials Grant Program PAR-24-072 (R01 Clinical Trial Required) 01/08/2027 NCI Clinical and Translational Exploratory/Developmental Studies PAR-22-216 (R21 Clinical Trial Optional) 07/02/2025 - Disparities, Equity
-
Title Announcement and Link Expiration Date Administrative Supplements to Support Cancer Disparity Collaborative Research PAR-22-114 (Clinical Trial Optional) 01/24/2025 Notice of Special Interest (NOSI): Administrative Supplements for Enhancing Recruitment and Retention of Diverse Populations to Cancer Screening, Cancer Prevention and Symptom Management Clinical Trials NOT-CA-23-071 07/01/2025 Basic Research in Cancer Health Disparities PAR-21-322 (R01 Clinical Trial Not Allowed)
PAR-21-323 (R21 Clinical Trial Not Allowed)
PAR-21-324 (R03 Clinical Trial Not Allowed)09/08/2024 Notice of Special Interest: Increasing Uptake of Evidence Based Screening in Diverse Populations Across the Lifespan NOT-OD-22-178 05/08/2025 Investigator-Initiated Research in Genomics and Health Equity RFA-HG-23-017 (R01 Clinical Trial Optional) 07/09/2025 Notice of Special Interest: Data Informed, Place-Based Community-Engaged Research to Advance Health Equity NOT-HL-23-110 01/08/2027 Notice of Special Interest: Research to Address Vaccine Uptake and Implementation among Populations Experiencing Health Disparities NOT-MD-23-008 06/06/2026 Risk and Protective Factors of Family Health and Family Level Interactions PAR-21-358 (R01 Clinical Trial Optional) 05/08/2025 - Obesity
-
Title Announcement and Link Expiration Date Mechanisms that Impact Cancer Risk after Bariatric Surgery PAR-21-332 (R21 Clinical Trial Not Allowed)
PAR-21-331 (R01 Clinical Trial Optional)09/08/2024 Notice of Special Interest (NOSI): Mechanisms Driving Obesity and Prostate Cancer Risk NOT-CA-23-089 09/08/2024 Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics PAR-23-279 (R01 Clinical Trial Optional)
PAR-23-280 (R21 Clinical Trial Not Allowed)01/08/2027 - Technology
-
Title Announcement and Link Expiration Date Innovative Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research RFA-CA-24-008 (R61 Clinical Trial Not Allowed) 10/02/2024 Revision Applications for Incorporation of Novel NCI- Supported Technology to Accelerate Cancer Research RFA-CA-24-013 (U01 Clinical Trial Optional) 10/02/2024 Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research RFA-CA-24-012 (R01 Clinical Trial Optional) 10/02/2024 Advanced Development and Validation of Emerging Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research RFA-CA-24-009 (R33 Clinical Trial Not Allowed) 10/02/2024 Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research RFA-CA-24-014 (P50 Clinical Trial Optional) 10/02/2024 Cancer Tissue Engineering Collaborative: Enabling Biomimetic Tissue-Engineered Technologies for Cancer Research PAR-22-099 (R01 Clinical Trial Optional) 05/08/2025 Molecular Imaging of Inflammation in Cancer PAR-21-294 (R01 Clinical Trial Not Allowed) 01/08/2025 Notice of Special Interest: Validation of Digital Health and Artificial Intelligence/Machine Learning Tools for Improved Assessment in Biomedical and Behavioral Research NOT-CA-24-031 07/06/2025 - Diet and Natural Products
-
Title Announcement and Link Expiration Date Notice of Special Interest (NOSI): Dietary Effects on Nutrient Sensing Pathways in Tumor Etiology and Prevention NOT-CA-21-121 09/08/2024 Modulating Human Microbiome Function to Enhance Immune Responses Against Cancer PAR-22-061 (R01 Clinical Trial Not Allowed) 01/08/2025 Discovery and Development of Natural Products for Cancer Interception and Prevention RFA-CA-23-028 (UG3/UH3 Clinical Trial Not Allowed) 06/14/2025 Mechanistic links between diet, lipid metabolism, and tumor growth and progression PAR-23-051 (U01 Clinical Trial Not Allowed)
PAR-23-052 (UH2 Clinical Trial Not Allowed)10/24/2025 - Etiology and Early Detection
-
Title Announcement and Link Expiration Date Notice of Special Interest (NOSI): Research on the Etiology, Early Detection, Screening and Prevention of Early-Onset Colorectal Cancer NOT-CA-23-018 09/08/2024 Utilizing the PLCO Biospecimens Resource to Bridge Gaps in Cancer Etiology and Early Detection Research PAR-21-330 (U01 Clinical Trial Not Allowed) 10/12/2024 - Biomarkers and Biology
-
Title Announcement and Link Expiration Date Notice of Special Interest (NOSI): Utilization of Cohorts and Prospective Study Designs for Liquid Biopsy Assay Validation for Early Detection of Cancers NOT-CA-23-004 07/02/2025 Imaging, Biomarkers and Digital Pathomics for the Early Detection of Premetastatic Cancer and Precancerous Lesions Associated with Lethal Phenotypes PAR-22-131 (R01 Clinical Trial Optional) 09/08/2025 Assay Validation of High Quality Markers for Clinical Studies in Cancer PAR-23-313 (UH2/UH3 Clinical Trials Not Allowed)
PAR-23-314 (UH3 Clinical Trials Not Allowed)10/15/2026 Biology of Bladder Cancer PAR-22-218 (R01 Clinical Trial Optional)
PAR-22-219 (R21 Clinical Trial Optional)09/08/2025 Research Projects to Enhance Applicability of Mammalian Models for Translational Research PAR-23-281 (R01 Clinical Trial Not Allowed) 09/08/2026 Notice of Special Interest (NOSI): Exploratory Cancer Immunology Projects and Technologies (ExCITe) NOT-CA-24-016 11/17/2026 Notice of Special Interest (NOSI): Research Projects to Develop Oncoaging Models for Cancer Research NOT-CA-23-092 07/31/2027 Notice of Special Interest (NOSI): Conferences and Scientific Meetings in Cancer Biology NOT-CA-24-059 12/13/2024 - Alcohol and Tobacco Control
-
Title Announcement and Link Expiration Date Tobacco Regulatory Science RFA-OD-23-017 (R01 Clinical Trial Optional) 05/05/2025 Screening, Brief Intervention and Referral to Treatment or Prevention for Alcohol, Tobacco, and Other Drugs Use and Misuse in Adult Populations that Experience Health Disparities PAR-23-270 (R01 Clinical Trial Required) 05/08/2027 Notice of Special Interest: Epidemiology and Prevention in Alcohol Research NOT-AA-23-018 09/06/2026 Population Approaches to Reducing Alcohol-related Cancer Risk PAR-23-244 (R01 Clinical Trial Optional) 01/08/2027
This list includes selected funding opportunities. Additional relevant funding opportunities are available on the following National Cancer Institute websites: